6
Participants
Start Date
January 31, 2006
Primary Completion Date
February 28, 2009
Study Completion Date
February 28, 2009
Efalizumab
Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Eye Institute (NEI)
NIH